Neumora Therapeutics (NASDAQ:NMRA) President Joshua Pinto Sells 5,967 Shares

Neumora Therapeutics, Inc. (NASDAQ:NMRA) President Joshua Pinto sold 5,967 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $3.54, for a total transaction of $21,123.18. Following the transaction, the president owned 57,783 shares in the company, valued at $204,551.82. The trade was a 9.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Neumora Therapeutics Stock Performance

NASDAQ NMRA traded down $0.10 on Friday, hitting $3.39. 364,898 shares of the company’s stock traded hands, compared to its average volume of 2,272,368. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The firm’s 50-day moving average price is $2.18 and its two-hundred day moving average price is $2.06. Neumora Therapeutics, Inc. has a 1-year low of $0.61 and a 1-year high of $3.65. The firm has a market capitalization of $565.60 million, a PE ratio of -2.30 and a beta of 3.20.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Legacy Private Trust Co. boosted its stake in Neumora Therapeutics by 35.7% during the 4th quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock worth $34,000 after purchasing an additional 5,000 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in Neumora Therapeutics by 10.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company’s stock valued at $117,000 after acquiring an additional 6,233 shares in the last quarter. Invesco Ltd. raised its holdings in Neumora Therapeutics by 6.8% in the 2nd quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock valued at $97,000 after acquiring an additional 8,383 shares during the last quarter. CWM LLC boosted its holdings in shares of Neumora Therapeutics by 41.8% during the 2nd quarter. CWM LLC now owns 35,750 shares of the company’s stock worth $26,000 after purchasing an additional 10,537 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Neumora Therapeutics during the 3rd quarter worth approximately $31,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on NMRA shares. Guggenheim upgraded Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Monday, October 27th. Royal Bank Of Canada upgraded Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $4.00 to $7.00 in a research report on Monday, December 1st. Mizuho set a $6.00 target price on Neumora Therapeutics in a research note on Monday, January 5th. Leerink Partners assumed coverage on shares of Neumora Therapeutics in a research note on Monday, January 12th. They issued an “outperform” rating and a $8.00 price target on the stock. Finally, Needham & Company LLC boosted their price target on shares of Neumora Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $8.13.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.